|
|
|
|
|||||
|
|
|
Indivior is already profitable and cash-generative, and is set to grow significantly in 2026.
Its key medication's delivery system offers opioid use disorder patients more reliable outcomes.
Shares in Indivior Plc (NASDAQ: INDV) were up by 15.5% at 1 p.m. ET today after management released an excellent set of third-quarter results, upgraded its full-year guidance, and served notice that its "Indivior Action Agenda" three-phase plan is generating momentum as the profitable and cash-generative company grows sales of its key prescription medication Sublocade.
According to Indivior, Sublocade is "indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine."
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Sublocade contains buprenorphine, but its delivery system offers a monthly dosage compared to the daily dosage regimen of buprenorphine -- something that can be a significant benefit for opioid use disorder sufferers.
It's Indivior's key medication, and a key part of the pharmaceutical company's three-phase plan is to grow sales in the U.S. This is being achieved by increasing U.S. Sublocade sales by 7% in the first nine months of 2025 compared to the same period in 2024. Moreover, management updated its full-year guidance for total Sublocade sales to $825 million to $845 million, compared to previous guidance for $765 million to $785 million.
Image source: Getty Images.
Management is also aiming for $150 million in annual expense savings in 2026 through restructuring and consolidating its operating footprint, while engaging in the second phase (accelerating Sublocade revenue growth in the U.S. and converting it into earnings and cash flow generation) before moving on to the third phase (using the improved financial profile to generate growth through acquisitions).
While the uniqueness of the "action agenda" is debatable, the progress made by the company is not, and if it can maintain the sales momentum established in 2025, the future looks bright.
Before you buy stock in Indivior Plc, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Indivior Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $593,442!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,269,127!*
Now, it’s worth noting Stock Advisor’s total average return is 1,071% — a market-crushing outperformance compared to 196% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 27, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
| 46 min | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 | |
| Oct-29 | |
| Oct-28 | |
| Oct-23 | |
| Oct-16 | |
| Oct-15 | |
| Oct-01 | |
| Sep-30 | |
| Sep-10 | |
| Sep-09 | |
| Aug-20 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite